Thomas M. Savage

Thomas M. Savage

Auto-generated profile, based on publicly available information

Thomas M. Savage

Department of Microbiology & Immunology, Columbia University, New York, NY 10032, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
SBSonakshi Bhattacharjee
Sonakshi Bhattacharjee
FHFlorian Hamberger
Florian Hamberger
ARAashreya Ravichandra
Aashreya Ravichandra
MMMaximilian Miller
Maximilian Miller
ANAjay Nair
Ajay Nair
RSRobert F. Schwabe
Robert F. Schwabe
Cancer-associated fibroblasts (CAF) may exert tumor-promoting and tumor-suppressive functions, but the mechanisms underlying these opposing effects remain elusive. Here, we sought to understand these potentially opposing functions by interrogating functional relationships among CAF subtypes, their mediators, desmoplasia, and tumor growth in a wide range of tumor types metastasizing to the liver, the most common organ site for metastasis. Depletion of hepatic stellate cells (HSC), which represented the main source of CAF in mice and patients in our study, or depletion of all CAF decreased tumor growth and mortality in desmoplastic colorectal and pancreatic metastasis but not in nondesmoplastic metastatic tumors. Single-cell RNA-Seq in conjunction with CellPhoneDB ligand-receptor analysis, as well as studies in immune cell–depleted and HSC-selective knockout mice, uncovered direct CAF-tumor interactions as a tumor-promoting mechanism, mediated by myofibroblastic CAF–secreted (myCAF-secreted) hyaluronan and inflammatory CAF–secreted (iCAF-secreted) HGF. These effects were opposed by myCAF-expressed type I collagen, which suppressed tumor growth by mechanically restraining tumor spread, overriding its own stiffness-induced mechanosignals. In summary, mechanical restriction by type I collagen opposes the overall tumor-promoting effects of CAF, thus providing a mechanistic explanation for their dual functions in cancer. Therapeutic targeting of tumor-promoting CAF mediators while preserving type I collagen may convert CAF from tumor promoting to tumor restricting.

5 October 2022 in Nature
Verified
Journal Article
Closed access
PDF file
AFAveline Filliol
Aveline Filliol
YSYoshinobu Saito
Yoshinobu Saito
ANAjay Nair
Ajay Nair
DDDianne H. Dapito
Dianne H. Dapito
LYLe-Xing Yu
Le-Xing Yu
RSRobert F. Schwabe
Robert F. Schwabe

1 June 2021 in Cancer Cell
Verified
Journal Article
Closed access
SASilvia Affo
Silvia Affo
ANAjay Nair
Ajay Nair
FBFrancesco Brundu
Francesco Brundu
ARAashreya Ravichandra
Aashreya Ravichandra
SBSonakshi Bhattacharjee
Sonakshi Bhattacharjee
RSRobert F. Schwabe
Robert F. Schwabe

13 October 2023 in Science
Verified
Journal Article
Closed access
RVRosa L. Vincent
Rosa L. Vincent
CGCandice R. Gurbatri
Candice R. Gurbatri
FLFangda Li
Fangda Li
AVAna Vardoshvili
Ana Vardoshvili
CCCourtney Coker
Courtney Coker
TDTal Danino
Tal Danino
A major challenge facing tumor-antigen targeting therapies such as chimeric antigen receptor (CAR)–T cells is the identification of suitable targets that are specifically and uniformly expressed on heterogeneous solid tumors. By contrast, certain species of bacteria selectively colonize immune-privileged tumor cores and can be engineered as antigen-independent platforms for therapeutic delivery. To bridge these approaches, we developed a platform of probiotic-guided CAR-T cells (ProCARs), in which tumor-colonizing probiotics release synthetic targets that label tumor tissue for CAR-mediated lysis in situ. This system demonstrated CAR-T cell activation and antigen-agnostic cell lysis that was safe and effective in multiple xenograft and syngeneic models of human and mouse cancers. We further engineered multifunctional probiotics that co-release chemokines to enhance CAR-T cell recruitment and therapeutic response.

10 March 2023 in Science Advances
Verified
Journal Article
Closed access
TSThomas M. Savage
Thomas M. Savage
RVRosa L. Vincent
Rosa L. Vincent
SRSarah S. Rae
Sarah S. Rae
LHLei Haley Huang
Lei Haley Huang
AAAlexander Ahn
Alexander Ahn
NANicholas Arpaia
Nicholas Arpaia
Tumors use multiple mechanisms to actively exclude immune cells involved in antitumor immunity. Strategies to overcome these exclusion signals remain limited due to an inability to target therapeutics specifically to the tumor. Synthetic biology enables engineering of cells and microbes for tumor-localized delivery of therapeutic candidates previously unavailable using conventional systemic administration techniques. Here, we engineer bacteria to intratumorally release chemokines to attract adaptive immune cells into the tumor environment. Bacteria expressing an activating mutant of the human chemokine CXCL16 (hCXCL16 K42A ) offer therapeutic benefit in multiple mouse tumor models, an effect mediated via recruitment of CD8 + T cells. Furthermore, we target the presentation of tumor-derived antigens by dendritic cells, using a second engineered bacterial strain expressing CCL20. This led to type 1 conventional dendritic cell recruitment and synergized with hCXCL16 K42A -induced T cell recruitment to provide additional therapeutic benefit. In summary, we engineer bacteria to recruit and activate innate and adaptive antitumor immune responses, offering a new cancer immunotherapy strategy.

12 March 2025 in Nature
Verified
Journal Article
Open access
PDF file
ASAtsushi Sugimoto
Atsushi Sugimoto
YSYoshinobu Saito
Yoshinobu Saito
GWGuanxiong Wang
Guanxiong Wang
QSQiuyan Sun
Qiuyan Sun
CYChuan Yin
Chuan Yin
RSRobert F. Schwabe
Robert F. Schwabe
Hepatic stellate cells (HSCs) have a central pathogenetic role in the development of liver fibrosis. However, their fibrosis-independent and homeostatic functions remain poorly understood1–5. Here we demonstrate that genetic depletion of HSCs changes WNT activity and zonation of hepatocytes, leading to marked alterations in liver regeneration, cytochrome P450 metabolism and injury. We identify R-spondin 3 (RSPO3), an HSC-enriched modulator of WNT signalling, as responsible for these hepatocyte-regulatory effects of HSCs. HSC-selective deletion of Rspo3 phenocopies the effects of HSC depletion on hepatocyte gene expression, zonation, liver size, regeneration and cytochrome P450-mediated detoxification, and exacerbates alcohol-associated and metabolic dysfunction-associated steatotic liver disease. RSPO3 expression decreases with HSC activation and is inversely associated with outcomes in patients with alcohol-associated and metabolic dysfunction-associated steatotic liver disease. These protective and hepatocyte-regulating functions of HSCs via RSPO3 resemble the R-spondin-expressing stromal niche in other organs and should be integrated into current therapeutic concepts.